Triastek, Inc. is a pioneering global leader in 3D printing pharmaceuticals, with a mission to revolutionize the pharmaceutical industry and benefit patients worldwide. Founded in July 2015, the company has developed the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, aimed at transforming medication delivery, development, and production through digital product development and continuous manufacturing. Triastek leverages its proprietary 3D printing pharmaceutical technology to design and develop transformative medications, working in collaboration with global pharmaceutical companies to address formulation issues and accelerate the development of new drug products. With its headquarters in China, Triastek recently secured a significant CNY150.00M Series C investment on 28 September 2023, with notable investors including Guoxin Investment, Xiaodong Zheng, and Goldmine Multi-family Office. As the company strives to become the world's most influential intelligent pharmaceutical enterprise, its innovative approach and recent investments position it as a key player in the future of pharmaceutical manufacturing and development.
Triastek, Inc.
Creating New Dimensions
Nanjing, China
36 employees
Series C
Total: $680.00M
Manufacturing, Pharmaceutical +1
General Information
Get notified when Triastek, Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Triastek, Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
China Market
Manufacturing
About Triastek, Inc.
Taxonomy: 3D Printing, Pharmaceuticals, Digital Product Development, Continuous Manufacturing, Drug Formulation, Intellectual Property, Medical Technology, Medication Innovation, Biopharmaceuticals, Pharmaceutical Technology, Drug Development, Global Collaboration
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | •••••• | 3 |
|
28 Sep 2023 |
| Series B | •••••• | 3 |
|
23 Nov 2021 |
| Series B | •••••• | 7 |
|
24 Jun 2021 |
| Series A | •••••• | 3 |
|
15 Dec 2020 |
| Series A | •••••• | 3 |
|
01 Jun 2018 |
Triastek, Inc. Alternatives & Competitors
Leader in pharmaceutical films
Affordable. Accessible. Quality Medicines
Athenex is a global specialty oncology pharmaceutical company focused on the development and commerc...
FAQ About Triastek, Inc.
Don't just browse. Track.
Signal Tracker monitors Triastek, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.